Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5N1 VLP vaccine + adjuvant 2
- Development stage
- Unknown
- Lead developer
- Medicago
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
H5N1 VLP vaccine + adjuvant 2 refers to a specific investigational vaccine formulation developed by Novavax for the prevention of H5N1 avian influenza. The vaccine component consists of virus-like particles (VLPs) produced using recombinant baculovirus technology in insect cells (Sf9). These VLPs are engineered to express the hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins of the A/Indonesia/05/2005 (H5N1) strain, mimicking the structure of the wild-type virus without containing genetic material. Adjuvant 2 refers to a specific adjuvant formulation—typically a higher dose of aluminum hydroxide (alum) or a proprietary adjuvant system—used in clinical trials to enhance the magnitude and breadth of the immune response. The combination was evaluated in Phase 1 and Phase 2 clinical trials to assess safety and immunogenicity, particularly its ability to induce neutralizing antibodies against highly pathogenic avian influenza.
- Other names
- H5N1 VLP + Adjuvant 2Novavax H5N1 VLP vaccine + adjuvant 2
02
Targets
M1 (Muscarinic acetylcholine receptor M1)HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on H5N1 VLP vaccine + adjuvant 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5N1 VLP vaccine + adjuvant 2.